Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer
Developing Clinical High Efficiency Platforms for Individualised Treatment Through Integration of Advanced Radiation Technology, Quantitative Imaging and Molecular Biology and Machine Learning for Treatment of Cervix Cancer.
Tata Memorial Hospital
1,800 participants
Feb 24, 2022
OBSERVATIONAL
Conditions
Summary
Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.
Eligibility
Inclusion Criteria3
- For Aim 1 and Aim 3:
- Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy For Aim 2
- Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.
Exclusion Criteria2
- Lack of disease or toxicity outcomes.
- Lack of images in the hospital database.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05102240